Business Wire

CGTN

10.3.2021 14:26:12 CET | Business Wire | Press release

Share
CGTN: UK Regulator Criticized for 'Act of Censorship' by Banning CGTN

Britain's communications regulator Ofcom has been criticized for its decision to ban and fine China Global Television Network (CGTN) for political reasons.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005537/en/

A group of journalists, filmmakers and artists recently challenged Ofcom's "act of censorship" in an open letter published by the No Cold War campaign and the Morning Star.

"The decision by Ofcom to remove the broadcasting license of CGTN is an act of censorship which is not in the interests of Britain and its people," the open letter said, calling the move an "attack on free speech."

Ofcom revoked the license of CGTN to broadcast in the UK in early February on the grounds of its ultimate control and its political attributes. Beijing slammed the move as political repression against Chinese media.

In their letter, the signatories questioned Ofcom's justification for banning CGTN.

"Ofcom's justification for taking CGTN off air is that any holder of a broadcasting license in Britain must not be controlled by political bodies. However, this law is only selectively applied. Numerous private and state channels have clear political agendas or control – the BBC itself, for example, which had its staff vetted by MI5, has not had its broadcasting license revoked," it said.

The letter urged Ofcom to reverse its decision and reinstate CGTN's license.

CGTN committed to balanced reporting

A spokesperson for CGTN on Tuesday called on the British regulator to calmly listen to the opinions expressed in the letter and end its political crackdown on Chinese media.

The spokesperson said that as an international news channel, CGTN is committed to providing "accurate, timely and objective news and information with diverse and balanced views" for its global audiences.

"China is increasingly connected and engaged with the rest of the world including the UK," the spokesperson said in a statement. "It is our responsibility to present Chinese viewpoints and perspectives in our news reporting, which is what our viewers expect and is also in the interest of the public."

'The world should be able to hear China's voice'

In a separate statement on Tuesday, CGTN said it is disappointed with and firmly opposes Ofcom's latest sanction decisions and adjudications against it.

Ofcom on Monday fined CGTN 225,000 British pounds (about $310,933) for "breaching rules on fairness, privacy and due impartiality" just weeks after it stripped the network of its right to air in Britain.

"CGTN believes its coverage of the 2019 violent protests in the Hong Kong Special Administrative Region was fair, truthful and duly impartial," the statement said.

"As a news outlet from China, CGTN made it possible for global audiences to see and hear a more complete picture of events in Hong Kong by reporting on the voices opposing violence and destruction," it stressed. "The fact that CGTN has been sanctioned by Ofcom for its objective coverage of the event is unjust."

"It is in the public interest that the world should be able to hear China's voice and perspective and see the true picture more clearly," it added.

At a regular press briefing on Tuesday, Chinese Foreign Ministry spokesperson Zhao Lijian urged Ofcom and certain individuals to immediately cease engaging in political manipulation and correct their mistakes, slamming the move as "blatant political oppression."

https://news.cgtn.com/news/2021-03-10/UK-regulator-criticized-for-act-of-censorship-by-banning-CGTN-YvNehReHaE/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye